Barclays’s VanEck Biotech ETF BBH Stock Holding History

Barclays’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,700	Closed	-$461K	–	7054
2017 Q4	$461K	Sell	3,700 -1,700	-31%	-$217K	﹤0.01%	3916
2017 Q3	$724K	Buy	+5,400	New	+$703K	﹤0.01%	3286

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Barclays's BBH Position: Q4 2021 in Review

Barclays sold out of VanEck Biotech ETF (BBH) in Q4 2021, closing a stake of 3 shares — an estimated $1K sold.

Barclays first reported a position in BBH in Q3 2017 and held it in 3 quarters. The position peaked at $124K in Q2 2021. 126 funds tracked by Wall St. Rank hold BBH as of Q4 2021.

Barclays reported no remaining VanEck Biotech ETF position as of Q4 2021 after selling out during the quarter.
Barclays sold 3 VanEck Biotech ETF shares in Q4 2021, an estimated $1K.
Barclays first reported a position in VanEck Biotech ETF in Q3 2017 and held it in 3 quarters.
Barclays's VanEck Biotech ETF position peaked at $124K in Q2 2021.
126 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.